Street Calls of the Week
Director Lucas Svetlana of Jasper Therapeutics (NASDAQ:JSPR) acquired 20,000 shares of voting common stock at $2.43 on September 22, 2025, near the stock’s 52-week low of $2.27. The purchase comes as the micro-cap biotech company, valued at $37.87 million, has seen its shares decline nearly 89% over the past year. According to InvestingPro analysis, the stock appears undervalued, with analysts setting price targets ranging from $4 to $51. The total value of this purchase was $48,600.
The same day, Lucas also acquired 20,000 Common Stock Warrants, each entitling her to buy one share of voting common stock at an exercise price of $2.92. These warrants expire on March 22, 2030, and become exercisable on March 22, 2026.
In other recent news, Jasper Therapeutics has announced a public offering expected to raise approximately $30 million in gross proceeds. The offering includes 11,670,707 shares of common stock with accompanying warrants priced at $2.43 per share and 675,000 pre-funded warrants. These common warrants will be exercisable at $2.92 per share starting six months after issuance and will be valid for four years. This development follows the company’s announcement of its intention to launch the offering, which is subject to market conditions. Analysts at JMP Securities and BTIG have responded to this news by lowering their price targets for Jasper Therapeutics, citing dilution from the offering. JMP Securities has reduced its target to $6 while maintaining a Market Outperform rating. Meanwhile, BTIG has adjusted its target to $7, maintaining a Buy rating. The company plans to use the proceeds to advance the development of briquilimab, a therapy targeting KIT (CD117) for mast cell-driven diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.